Keros Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell KROS and other ETFs, options, and stocks.About KROS
Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need.
CEOJasbir S. Seehra
CEOJasbir S. Seehra
Employees169
Employees169
HeadquartersLexington, Massachusetts
HeadquartersLexington, Massachusetts
Founded2015
Founded2015
Employees169
Employees169
KROS Key Statistics
Market cap617.24M
Market cap617.24M
Price-Earnings ratio11.73
Price-Earnings ratio11.73
Dividend yield—
Dividend yield—
Average volume1.30M
Average volume1.30M
High today$20.35
High today$20.35
Low today$17.95
Low today$17.95
Open price$18.10
Open price$18.10
Volume1.19M
Volume1.19M
52 Week high$72.37
52 Week high$72.37
52 Week low$9.12
52 Week low$9.12
Stock Snapshot
With a market cap of 617.24M, Keros Therapeutics(KROS) trades at $20.01. The stock has a price-to-earnings ratio of 11.73.
On 2025-12-05, Keros Therapeutics(KROS) stock moved within a range of $17.95 to $20.35. With shares now at $20.01, the stock is trading +11.5% above its intraday low and -1.7% below the session's peak.
Trading activity shows a volume of 1.19M, compared to an average daily volume of 1.3M.
The stock's 52-week range extends from a low of $9.12 to a high of $72.37.
The stock's 52-week range extends from a low of $9.12 to a high of $72.37.
Analyst ratings
56%
of 9 ratingsBuy
55.6%
Hold
44.4%
Sell
0%
People also own
Based on the portfolios of people who own KROS. This list is generated using Robinhood data, and it’s not a recommendation.